Skip to content
Peptide research

Testagen

Category
Bioregulators
Administration routes
InjectableOral
Regulatory status
Not FDA-approved

A synthetic four-amino-acid peptide marketed as a bioregulator for testosterone normalization and male reproductive support. The case rests on mechanistic and in vitro work from largely one research group, with essentially no independent human data behind the touted testosterone or thyroid effects. There is no formal human safety profile, and supply is unregulated research-grade product. Not an FDA-approved drug, with no established clinical indication.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Testagen is a synthetic 4-amino-acid peptide (KEDG) from the Khavinson bioregulator family, originally derived from testicular tissue extracts. Developed at the St. Petersburg Institute of Bioregulation and Gerontology in Russia, it is designed to support male reproductive function by influencing gene expression in the cells responsible for testosterone production. It is the purified synthetic version of the natural complex called Testoluten.

How it works in the body

A tetrapeptide bioregulator (Lys-Glu-Asp-Gly) that targets Leydig cells in the testes and adrenal tissue. It interacts with gene regulatory regions to modulate the expression of enzymes in the testosterone synthesis pathway, including StAR protein and CYP enzymes involved in steroidogenesis.

Research overview

Rather than binding to cell-surface receptors like most drugs, Testagen is proposed to enter cells and interact directly with DNA and histone proteins, influencing which genes are turned on or off — a form of epigenetic regulation. Lab studies show it accumulates in cell nuclei and preferentially binds to specific DNA sequences. One clinical study of the parent compound Testoluten in 36 men (ages 43-61) showed a 26% increase in testosterone over 10 days. Research also suggests effects on thyroid function in animal models. However, nearly all published studies come from a single Russian research group, no randomized controlled trials of the pure synthetic peptide exist in humans, and independent Western replication is essentially absent.

Who researches Testagen?

Commonly researched by

  • People researching testosterone normalization and male reproductive support

    One of the primary studied benefits of Testagen.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • No formal human safety profile established

    High

    ClinicalTrials.gov: no Testagen/KEDG trials; PubMed: no human studies

  • All safety data from a single research group without independent verification

    High

    PMIDs 23658898, 22268052, 21809626, 19024016, 20731122 (same group); PMID 40807317 (unrelated materials-science use)

  • Research-grade product quality and purity concerns

    High

    FDA compounding bulk substances lists; no NDA/ANDA for Testagen

  • Potential hormonal disruption

    Theoretical

    PMID 22268052; PMID 19024016

  • Unknown long-term effects of epigenetic modulation

    Theoretical

    PMID 22117547; PMID 23581987

  • Injection site reactions

    Low

    Class effect; no Testagen-specific data

Interaction summary(7)

Rated by direction with this peptide

  • Levothyroxine and other thyroid hormone replacement

    CautionTheoretical

    KEDG altered thyroid follicular structure and hormonal output in hypophysectomized birds, so co-administration could in principle shift endogenous thyroid hormone production and destabilize a titrated levothyroxine dose; no human interaction has been observed or measured.

    PMID 22268052; PMID 19024016; PMID 21809626

  • Antithyroid drugs (methimazole, propylthiouracil)

    CautionTheoretical

    A peptide claimed to restore thyroid follicular function works against the therapeutic goal of thyroid suppression in hyperthyroidism, making it a mechanistically opposing agent rather than a documented pharmacologic interaction.

    PMID 22268052; PMID 20731122

  • Warfarin, DOACs, and antiplatelet agents

    CautionTheoretical

    KEDG reportedly normalized hypercoagulation and depressed fibrinolysis in hypophysectomized birds, so any effect on coagulation or fibrinolytic balance could theoretically add to or oppose anticoagulant therapy; there is no human coagulation data and no case report.

    PMID 20731122

  • Testosterone replacement therapy and anabolic androgens

    CautionTheoretical

    Testagen is marketed for endogenous testosterone support, which is pharmacologically redundant with exogenous androgens that already suppress the HPG axis; the interaction is conceptual since no study has ever shown KEDG changes testosterone.

    Mechanism-based; no primary evidence of KEDG testosterone effect

  • hCG, clomiphene, and enclomiphene (HPG-axis stimulators)

    NeutralTheoretical

    Complementary Leydig-cell support with gonadotropin-axis stimulators is sometimes assumed, but no study has ever shown KEDG affects the HPG axis or testosterone, so no synergy has been demonstrated. There is no documented pharmacodynamic interaction; any claimed combined benefit is marketing-level inference only.

    No primary evidence; mechanism-only inference

  • Immunosuppressants and corticosteroids

    CautionTheoretical

    Reported thymic restoration and normalization of depressed immune parameters in birds would run counter to intentional immunosuppression after transplant or in autoimmune disease; no human immune endpoint has been measured for this peptide.

    PMID 23658898; PMID 20731122

  • Other Khavinson short peptides (Epithalon, Pinealon, Bronchogen)

    CautionTheoretical

    These peptides share overlapping methylation-sensitive DNA and histone binding sites in vitro, so using them together plausibly produces overlapping, non-additive, and wholly uncharacterized epigenetic exposure rather than independent effects.

    PMID 22117547; PMID 23581987

Known risks(6)

  • No formal human safety profile established

    High

    Pure Testagen (KEDG) has never been administered to humans in a controlled clinical trial with safety monitoring. Human reports concern Testoluten and an oral Testagen supplement; purified injectable KEDG safety remains unestablished. No Phase 1 safety/tolerability study has been conducted.

  • All safety data from a single research group without independent verification

    High

    Every preclinical and clinical study on Testagen/Testoluten was conducted by Khavinson's research network in Russia. The broader scientific community has called for larger-scale, independent clinical trials. Without independent replication, the safety profile cannot be considered established by modern pharmacological standards.

  • Research-grade product quality and purity concerns

    Moderate-High

    Commercially available Testagen is research-grade, not pharmaceutical-grade. Unregulated products sold online lack the quality controls (GMP manufacturing, sterility testing, endotoxin testing, stability data) required for injectable pharmaceuticals. Impurities in peptide synthesis could include truncated sequences, racemized amino acids, or residual solvents.

  • Potential hormonal disruption

    Moderate

    Testagen modulates the HPG and HPT axes. Exogenous administration could theoretically disrupt normal hormonal feedback loops, particularly in individuals with pre-existing thyroid conditions or those on thyroid or testosterone replacement therapy. Effects on estrogen, LH, FSH, and other pituitary hormones are not characterized.

  • Unknown long-term effects of epigenetic modulation

    Moderate

    Testagen interacts directly with DNA and histones to alter gene expression. The long-term consequences of exogenous epigenetic modification — particularly regarding cancer risk, developmental effects, or transgenerational impacts — are completely unknown.

  • Injection site reactions

    Low

    Subcutaneous or intramuscular injection of peptides commonly causes local reactions including redness, swelling, and pain at the injection site. This risk is consistent across the peptide class and is expected with Testagen.

Drug interactions(5)

  • Testosterone replacement therapy (TRT) and androgens

    Testagen is proposed to normalize testosterone production via Leydig cell stimulation and HPG axis modulation. Concurrent use with exogenous testosterone could create conflicting signals — TRT suppresses endogenous LH/FSH via negative feedback, while Testagen may attempt to upregulate endogenous production pathways. No clinical data on this interaction exists.

  • Thyroid hormones (levothyroxine, liothyronine) and antithyroid drugs

    Testagen (KEDG) has demonstrated significant thyroid-modulating effects in preclinical studies, normalizing TSH, T3, and T4 levels. In individuals on thyroid hormone replacement or antithyroid medications, Testagen could theoretically alter thyroid hormone levels in unpredictable ways, potentially requiring dose adjustments. This interaction is entirely theoretical but biologically plausible based on avian data.

  • Gonadotropins and GnRH analogs (leuprolide, clomiphene, hCG)

    Testagen modulates the HPG axis. Combined use with gonadotropin-stimulating agents or GnRH analogs could result in unpredictable additive or antagonistic effects on LH, FSH, and testosterone production. No data available.

  • Other Khavinson bioregulatory peptides (Epitalon, Thymalin, etc.)

    Khavinson's research group states that bioregulatory peptides show no cross-reactivity or competition with one another. However, this claim has not been independently verified. Multiple peptides acting on overlapping epigenetic mechanisms (DNA binding, histone modification) could theoretically have unpredictable combinatorial effects on gene expression.

  • Immunosuppressants and immunomodulators

    KEDG has demonstrated immune-normalizing effects (thymic recovery, immune parameter normalization in hypophysectomized models). This immunomodulatory activity could theoretically interfere with immunosuppressive therapy. No clinical data.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
12
Human Studies
1

The clinical evidence for Testagen is extremely limited. Evidence for purified KEDG remains predominantly preclinical. Human reports concern commercial preparations, including Testoluten and an oral Testagen supplement studied in 36 men during 2010–2011. The latter compared adjunctive treatment with standard treatment and did not report blinding or chemical verification of pure KEDG. These reports do not establish efficacy or safety of injectable KEDG. The Testoluten report (Khavinson et al. 2006) involved 36 men aged 43-61, with 19 receiving active treatment, and showed a 26% testosterone increase over 10 days; it was not registered on any clinical trial registry, was not independently replicated, and was conducted entirely within Khavinson's research network. The remaining evidence is preclinical: avian models for thyroid effects (multiple studies by Kuznik et al.), cell culture for DNA/histone interaction (Fedoreyeva et al.), and in vitro rat testicular explant cultures. No Western clinical trials, no ClinicalTrials.gov registrations, and no independent verification of any clinical claims exist. The broader Khavinson peptide bioregulator program claims over 15 years of clinical use in Russia with favorable safety, but these results lack independent validation.

Researched for(6)

Rated by confidence in the evidence

  • Testosterone normalization and male reproductive support

    Speculative

    No direct evidence in any species; testosterone effect is inferred, not measured, mechanism only.

    No PubMed record for KEDG and testosterone; peptide identity confirmed in PMID 22117547 (Fedoreyeva et al., Biochemistry (Mosc) 2011)

  • Thyroid hormone normalization and thyroid gland structural restoration

    Low

    Consistent animal studies show thyroid tissue and hormone recovery in birds; no human data yet.

    PMID 22268052; PMID 19024016; PMID 21809626; PMID 20731122

  • Thymic immune tissue restoration

    Speculative

    Single animal study showed thymus tissue recovery on histology alone, no functional immune tests.

    PMID 23658898 (Pateyk et al., Bull Exp Biol Med 2013)

  • Immune and hemostatic parameter normalization

    Speculative

    Single avian study found normalized immune and clotting markers; not independently replicated.

    PMID 20731122 (Kuznik et al., Patol Fiziol Eksp Ter 2010)

  • Epigenetic gene expression regulation via DNA and histone interaction

    Speculative

    In vitro studies show DNA and histone binding only; gene-expression regulation is unproven.

    PMID 22117547; PMID 23581987

  • Testicular tissue growth stimulation (in vitro)

    Speculative

    Cited only in vendor literature; no indexed study confirms this in vitro effect.

    No indexed primary source located (PubMed search for Khavinson peptide organotypic testis culture returned zero results)

Benefits(6)

  • Testosterone normalization and male reproductive support

    Khavinson et al. 2006 — Clinical study of Testoluten (natural testicular peptide complex from which Testagen is derived) in 36 men aged 43-61: 19 patients received 2.5 mg/ml IM daily for 10 days, showing a 26% increase in blood testosterone concentration vs. saline control. Patients reported improved sexual function, decreased symptoms of sexual weakness, and increased libido.

  • Thyroid hormone normalization and thyroid gland structural restoration

    Kuznik et al. 2008 (Bull Exp Biol Med, PMID 19024016) — KEDG administered to neonatally hypophysectomized chickens for 40 days increased thyrotropic hormone and thyroid hormone concentrations and recovered thyroid gland structure. Kuznik et al. 2011 (Bull Exp Biol Med, PMID 22268052) — KEDG significantly reduced hormonal disturbances and structural thyroid changes in hypophysectomized young chickens and old hens, with more pronounced effects in younger birds.

  • Thymic immune tissue restoration

    Pateyuk et al. 2013 (Bull Exp Biol Med, PMID 23658898) — KEDG promoted recovery of thymic morphological structures in hypophysectomized young and old birds, with KEDG (anterior pituitary peptide) showing more pronounced thymic recovery than AEDG (posterior pituitary peptide).

  • Immune and hemostatic parameter normalization

    Kuznik et al. 2010 (Patol Fiziol Eksp Ter, PMID 20731122) — KEDG injected into hypophysectomized birds prevented atrophic changes of the thyroid gland and normalized immune and hemostatic parameters.

  • Epigenetic gene expression regulation via DNA and histone interaction

    Fedoreyeva et al. 2011 (Biochemistry Moscow, PMID 22117547) — Fluorescence-labeled Testagen penetrated HeLa cell nuclei and nucleoli, bound preferentially to CAG-containing DNA sequences, and discriminated cytosine methylation status. Khavinson et al. 2021 (Molecules, PMID 34834147) — Systematic review confirmed KEDG binds histone proteins H1, H2B, H3, H4 at N-terminal motifs, increasing transcription availability of gene promoter zones.

  • Testicular tissue growth stimulation (in vitro)

    Khavinson et al. — When Testoluten (100 ng/ml) was added to organotypic culture of rat testes, it stimulated the growth of tissue explants by 35% compared to control.

Key studies(5)

  1. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF

    Biochemistry (Moscow)

    2011

    Fluorescein-labeled Testagen (KEDG) penetrated into the cytoplasm, nucleus, and nucleolus of HeLa cells. The peptide bound preferentially to CAG-containing DNA sequences and could discriminate between different nucleotide sequences and recognize cytosine methylation status, suggesting site-specific epigenetic control of gene expression.

  2. Effect of tetrapeptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the structure and function of the thyroid gland in neonatally hypophysectomized chickens

    Original research (preclinical, avian model)Neonatally hypophysectomized chickens40 days of peptide administration

    Kuznik BI, Pateyuk AV, Rusaeva NS

    Bulletin of Experimental Biology and Medicine

    2008

    Administration of KEDG to hypophysectomized chickens for 40 days increased concentrations of thyrotropic hormone and thyroid hormones (T3, T4) and recovered thyroid gland structure, demonstrating that this synthetic pituitary-derived tetrapeptide can partially restore thyroid function in the absence of the pituitary gland.

  3. Effects of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on hormonal activity and structure of the thyroid gland in hypophysectomized young chickens and old hens

    Original research (preclinical, avian model)Hypophysectomized young chickens and old hens40 days of peptide administration

    Kuznik BI, Pateyuk AV, Rusaeva NS, Baranchugova LM, Obydenko VI

    Bulletin of Experimental Biology and Medicine

    2011

    Both KEDG and AEDG significantly reduced hormonal disturbances and structural thyroid changes caused by hypophysectomy. The normalizing effect on TSH and thyroid hormones was less pronounced in old hens than in young chickens, indicating age-dependent responsiveness.

  4. Effect of peptides Lys-Glu-Asp-Gly and Ala-Glu-Asp-Gly on the morphology of the thymus in hypophysectomized young and old birds

    Original research (preclinical, avian model)Hypophysectomized young and old birds40 days of peptide administration

    Pateyuk AV, Baranchugova LM, Rusaeva NS, Obydenko VI, Kuznik BI

    Bulletin of Experimental Biology and Medicine

    2013

    KEDG promoted recovery of thymic morphological structures in hypophysectomized birds. The anterior pituitary peptide KEDG had a more pronounced effect on thymic structure recovery than the posterior pituitary peptide AEDG, regardless of the birds' ages.

  5. Peptide Regulation of Gene Expression: A Systematic Review

    Systematic reviewReview of peptide-gene regulation literature

    Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR

    Molecules

    2021

    Classified KEDG (Testagen) as a 'monofunctional peptide' regulating male reproductive system function. Confirmed that KEDG binds to histone proteins H1, H2B, H3, and H4 at N-terminal peptide-binding motifs, increasing transcription availability of gene promoter zones. Established the broader mechanistic framework for short peptide epigenetic regulation.

Regulation & availability

Why researchers look at it

A small clinical study of the parent compound Testoluten in 36 men showed a 26% testosterone increase over 10 days — but that single study was not randomized, not independently replicated, and used the natural extract rather than the synthetic tetrapeptide. If validated by independent Western trials, Testagen could offer a fundamentally different strategy for age-related testosterone decline by stimulating the body's own production rather than replacing it.

Estimated cost
$30-80/mo oral capsules
FDA status
Not FDA-approved for any indication. No publicly documented marketing approval or IND was identified; public records cannot establish that an application was never submitted. Testagen is absent from the published 503A and 503B interim categories, and no qualifying bulk-compounding basis was identified. Absence from a named FDA enforcement action does not exempt a product from drug law.
WADA status
Prohibited under S0 if no governmental health authority currently approves KEDG for human therapeutic use; no such approval was identified. Testagen is not individually named in the 2026 List, and a separate S4 classification was not established. TUE decisions follow WADA's medical criteria; no Testagen-specific entitlement or categorical ruling was identified.
Prescribability
Not FDA-approved. No qualifying basis for routine compounding from bulk under 503A or 503B was identified. Testagen is absent from the published interim-category lists. Category 1 provides conditional enforcement discretion while substances are evaluated; it is not an approval list. Dietary-supplement use in Russia does not establish pharmaceutical approval.
Availability
Testagen is NOT available as an approved pharmaceutical product in any major market. The natural complex Testoluten is available as an oral dietary supplement (capsules) containing natural testicular peptide extracts from animal tissue; Testoluten capsules are manufactured in Russia and shipped internationally. Testagen is NOT available through legitimate US compounding pharmacies, as it lacks the regulatory prerequisites (no USP monograph, no FDA Category 1 listing, not an active ingredient in any approved drug). No licensed clinics in the US or EU are known to prescribe or administer Testagen. Some anti-aging and longevity-focused practitioners may discuss it but cannot legally prescribe it. There is no legitimate prescription pathway for Testagen in the United States, European Union, or other major Western regulatory jurisdictions.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(7)

  1. 1990s
    Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology begin systematic isolation and characterization of organ-specific peptide bioregulators from animal tissues, including testicular extracts (Testoluten).
  2. 2006
    Khavinson et al. publish clinical study of Testoluten in 36 men (aged 43-61) showing 26% testosterone increase after 10 days of intramuscular injection at 2.5 mg/ml. This is the only published human clinical data for the testicular peptide bioregulator.
  3. 2008
    Kuznik et al. publish the first PubMed-indexed study specifically on the synthetic tetrapeptide KEDG (Testagen), demonstrating thyroid function restoration in hypophysectomized chickens (Bull Exp Biol Med, PMID 19024016).
  4. 2010-2013
    Series of publications by Kuznik, Pateyuk, Rusaeva et al. expand KEDG research in avian models: thyroid hormonal normalization (2010, 2011), immune/hemostatic parameter restoration (2010), thymic morphology recovery (2013).
  5. 2011
    Fedoreyeva et al. publish key mechanistic study (Biochemistry Moscow, PMID 22117547) demonstrating Testagen nuclear penetration, DNA binding specificity, and methylation recognition in HeLa cells.
  6. 2021-11
    Khavinson et al. publish systematic review 'Peptide Regulation of Gene Expression' (Molecules, PMID 34834147) classifying KEDG as a monofunctional peptide regulating male reproductive system function and confirming histone-binding mechanism.
  7. 2025-2026
    FDA tightens regulation of compounded peptides with updated Category 1/Category 2 bulk drug substance lists. Testagen is not named in Category 2 (BPC-157 and thymosin alpha-1 were, until April 2026) and remains ineligible for compounding: it has no USP monograph and no Category 1 designation.

Sources & FAQs

Research sources(15)

Frequently asked questions(5)

What is the difference between Testagen and Testoluten?

Testoluten is a natural peptide complex extracted from animal testicular tissue, containing a mixture of short peptides. Testagen (KEDG: Lys-Glu-Asp-Gly) is the purified, synthetically produced tetrapeptide identified as the primary active signaling molecule within Testoluten. Think of Testoluten as the crude extract and Testagen as the defined, single-sequence peptide derived from it. Testoluten is typically sold as oral capsules (dietary supplement), while Testagen is sold online as an unregulated powder.

Is Testagen the same as Epitalon (AEDG)?

No. Although both are Khavinson tetrapeptides with similar structures, they are distinct molecules with different sequences and functions. Testagen is KEDG (Lys-Glu-Asp-Gly), derived from anterior pituitary/testicular tissue, targeting male reproductive function. Epitalon is AEDG (Ala-Glu-Asp-Gly), derived from pineal gland tissue, targeting telomerase activation and circadian rhythm regulation. They share three of four amino acids (Glu-Asp-Gly) but differ in the first position (Lys vs. Ala), which determines tissue specificity.

Has Testagen been tested in human clinical trials?

Pure synthetic Testagen (KEDG) has not been tested in any registered human clinical trial. Human reports include Testoluten and a small 2011 study of oral Testagen supplement; neither establishes efficacy of purified injectable KEDG. The Testoluten study was conducted in Russia, was not registered on ClinicalTrials.gov, and has not been independently replicated. No Western clinical trials exist for either Testagen or Testoluten.

Why does Testagen also affect the thyroid gland?

Although originally isolated from testicular tissue, KEDG was later found to be synthesized based on the amino acid composition of anterior pituitary cytomedins (signaling peptides). The anterior pituitary produces both gonadotropins (LH, FSH) regulating reproductive function and thyrotropin (TSH) regulating thyroid function. KEDG appears to modulate the pituitary's broader endocrine signaling, explaining its dual effects on both the reproductive (HPG) and thyroid (HPT) axes.

Are there any safety concerns with Testagen?

Khavinson's group reports no significant toxic, allergic, or adverse effects from bioregulatory peptides, including toxicity studies at 300-3000 times the therapeutic dose. However, this safety data comes exclusively from Khavinson's own research network without independent verification. The peptide has never undergone formal regulatory safety review (IND, Phase 1). Research-grade product purity is a concern, and self-administration without medical supervision carries inherent risks from unregulated substances.